Small, consistent changeslike eating enough protein, choosing fibre-rich foods, and including healthy fatscan make a meaningful difference in how satisfied you feel after eating
Agache I, Akdis CA
Soliqua 100/33 (active ingredients: insulin glargine and lixisenatide) subcutaneous injection Initial FDA Approval: 2016 Side Effect Update Date: May 28, 2025 Medication Description: Treats type 2 diabetes Updated Side Effects/Safety Information: A new warning section on Severe Gastrointestinal Adverse Reactions. An additional new warning about the risk of serious kidney injury caused by dehydration due to gastrointestinal adverse effects like diarrhea and vomiting
Our team treats weight loss as the medical issue it is, with real clinical support and real human care
However, GLP-1 drugs were associated with a slightly higher rate of uveitis when compared with SGLT2i agents, which also conferred a reduced uveitis risk when compared with controls
The standard 12-week escalation from 0.6mg to 2.4mg weekly balances efficacy with tolerability, producing 10-12% weight loss for most users